Husseini K. Manji
Affiliations: | Laboratory of Molecular Pathophysiology and Experimental Therapeutics | National Institute of Mental Health (NIMH) |
Google:
"Husseini Manji"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Machado-Vieira R, Courtes AC, Zarate CA, et al. (2023) Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder. Frontiers in Neuroscience. 17: 1228455 |
| Ness S, Pandina G, Jagannatha S, et al. (2020) ASPI: a public-private partnership to develop treatments for autism. Nature Reviews. Drug Discovery. 19: 219-220 |
| Popova V, Daly EJ, Trivedi M, et al. (2019) Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. The American Journal of Psychiatry. appiajp201919020172 |
| Ochs-Ross R, Daly EJ, Zhang Y, et al. (2018) S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression Biological Psychiatry. 83 |
| Popova V, Daly E, Trivedi M, et al. (2018) S111. Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant Vs. Active Control in Treatment-Resistant Depression Biological Psychiatry. 83 |
| Tobe BTD, Crain AM, Winquist AM, et al. (2017) Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proceedings of the National Academy of Sciences of the United States of America |
| Breen G, Li Q, Roth BL, et al. (2016) Translating genome-wide association findings into new therapeutics for psychiatry. Nature Neuroscience. 19: 1392-1396 |
| Singh JB, Fedgchin M, Daly EJ, et al. (2016) A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. The American Journal of Psychiatry. appiajp201616010037 |
| Zarate CA, Quiroz J, Payne J, et al. (2016) Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacology Bulletin. 36: 35-83 |
| Bredt DS, Furey ML, Chen G, et al. (2015) Translating depression biomarkers for improved targeted therapies. Neuroscience and Biobehavioral Reviews |